<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844049</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.344</org_study_id>
    <nct_id>NCT02844049</nct_id>
  </id_info>
  <brief_title>European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS</brief_title>
  <acronym>EQOLOC</acronym>
  <official_title>European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS Versus Best Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obsessive-Compulsive Disorder (OCD) is among the most disabling psychiatric disorders as more
      than 40% of patients are resistant to the standard pharmacological and psychotherapy
      approaches and about 10% show severe disability and require institutionalization. These
      resistant patients may benefit from new surgical therapeutic approaches such as Deep Brain
      Stimulation (DBS) using high frequency stimulation of specific cerebral regions to modulate
      neural networks. Although promising, these results need nevertheless to be replicated and
      confirmed within a larger cohort of patients and considering a different main objective,
      instead of clinical improvement only. Indeed, despite a positive treatment response, adaptive
      functioning and quality of life may continue to be negatively impacted in OCD. Thus beyond
      symptom reduction, health-related quality of life (QoL) represents a more important objective
      of a treatment, as it includes both the individual's functional status and the individual's
      subjective perception of the impact of the illness on the patient's life. STN DBS induces
      significant clinical improvement, which may not be proportional to the QoL gain.
      Consequently, QoL appears to be a better outcome to target in the coming studies than
      clinical improvement alone. THe investigators thus propose a prospective study assessing the
      QoL changes of resistant OCD patients under STN DBS+BMT versus Best Medical Treatment (BMT)
      at 12 months, in order to assess the DBS induced gain in QoL in BMT-managed patients versus
      BMT alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will focus on an innovative therapeutic strategy (DBS) and on an original
      objective, quality of life, which is considered to better reflect the impact of a therapeutic
      strategy. Moreover, the study will help to define the predictive biomarkers /biosignatures of
      response to STN DBS in OCD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the impact of DBS+BMT versus BMT alone on a measure of Quality of life in resistant OCD patients at 1-year follow-up</measure>
    <time_frame>1 year</time_frame>
    <description>QOL assessment : scores at SF36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°1</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at YBOCS -Yale Brown Obsessive Compulsive Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°2</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at DYBOCS- Dimensional Yale Brown Obsessive Compulsive Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°3</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at YMRS (Young Mania Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°4</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at HAMA (Hamilton Rating Scale for Anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°5</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at STAI (State-Trait Anxiety Inventory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°6</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at UPPS-P Impulsive Behavior Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric assessment n°7</measure>
    <time_frame>1 year</time_frame>
    <description>clinical profile defined by score at Clinical Global Impression (Severity of OCD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°1</measure>
    <time_frame>1 year</time_frame>
    <description>Functioning scores : GAF (Global assessment functioning scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°2</measure>
    <time_frame>1 year</time_frame>
    <description>Functioning scores : WHODAS 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with side effects related to medical treatment, surgery and to stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric markers n°1</measure>
    <time_frame>1 year</time_frame>
    <description>scores at Big Five Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric markers n°2</measure>
    <time_frame>1 year</time_frame>
    <description>scores at BABS (BROWN ASSESSMENT OF BELIEFS SCALE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological markers n°3</measure>
    <time_frame>1 year</time_frame>
    <description>score at UPDRS (Unified Parkinson's Disease Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological markers n°4</measure>
    <time_frame>1 year</time_frame>
    <description>Score at OBQ-44 (Obsessive Beliefs Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological markers n°5</measure>
    <time_frame>1 year</time_frame>
    <description>Score at MCQ (Metacognitions questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological markers n°6</measure>
    <time_frame>1 year</time_frame>
    <description>Score at URICA (University Rhode Island Change Assessment Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological markers</measure>
    <time_frame>1 year</time_frame>
    <description>Score at Addenbrooke Cognitive Examination (ACE) battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-op electrophysiological mapping of the STN activity n°1</measure>
    <time_frame>1 year</time_frame>
    <description>electrophysiological parameters at rest and during OCD provocative tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-op electrophysiological mapping of the STN activity n°2</measure>
    <time_frame>1 year</time_frame>
    <description>electrophysiological parameters at rest and during OCD uncertainty test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-op electrophysiological mapping of the STN activity n°3</measure>
    <time_frame>1 year</time_frame>
    <description>electrophysiological parameters at rest and during OCD emotional test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-op electrophysiological mapping of the STN activity n°4</measure>
    <time_frame>1 year</time_frame>
    <description>electrophysiological parameters at rest and during OCD cognitive and motor test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the suicidal risk under DBS+BMT vs BMT in resistant OCD</measure>
    <time_frame>1 year</time_frame>
    <description>Measure of suicidal risk with MADRS scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Deep Brain Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DBS surgical procedure scheduled and realized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation</intervention_name>
    <description>surgical procedure</description>
    <arm_group_label>Deep Brain Stimulation</arm_group_label>
    <other_name>DBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OCD for &gt; 5 years

          -  YBOCS&gt; 25 and/or YBOCS sub-scale &gt;15

          -  GAF&lt; 45

          -  3 or more documented SRI trials, including clomipramine (10-12 weeks at adequate dose)

          -  SRI augmentation for &gt; 4 weeks with at least one antipsychotic and with one of the
             following: lithium, clonazepam

          -  Adequate trial of CBT (Exposure Therapy and Response Prevention) (intolerance or &gt;15
             sessions)

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Hoarding (if the only OCD symptom)

          -  OCD with poor insight (BABS score &gt; 12)

          -  Lifetime diagnosis of psychosis or bipolar disorder;

          -  Substance abuse or dependence within the previous six months;

          -  Baseline Montgomery and Asberg (MADRS) suicidality item (item 10) score &gt;2;

          -  Current DSM-5 personality disorder of Cluster A (e.g., paranoid or schizotypal
             personality disorder) or B (e.g., borderline or antisocial personality disorder);

          -  Brain pathology, such as moderate or marked cerebral atrophy, stroke, tumor or
             previous neurosurgical procedures (i.e. capsulotomy etc), history of cognitive
             impairment and cognitive deterioration (Addenbrooke's Cognitive Examination ACE score
             of &lt; 80).

          -  Contra-indications to surgery, anaesthesia, or MRI

          -  compulsory hospitalization/ care; pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mircea Polosan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra David-tchouda, MD</last_name>
    <phone>+33476767186</phone>
    <email>SDavidTchouda@chugrenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine Massicot, Master</last_name>
    <phone>+33476768860</phone>
    <email>smassicot@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc MALLET, MD PhD</last_name>
      <phone>33149813052</phone>
      <email>luc.mallet@upmc.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe DOMENECH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc MALLET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mircea POLOSAN, MD PhD</last_name>
      <phone>0033476765414</phone>
      <email>MPolosan@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Mircea Polosan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphan Chabardès, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Castrioto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Millet, MD PhD</last_name>
      <phone>33142162894</phone>
      <email>b.millet@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Carine KARACHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno MILLET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg (i.Br.)</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker COENEN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter GOLL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker COENEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln (AöR)</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veerle VISSER-VANDEWALLE, MD</last_name>
      <phone>+49 221 478-82793</phone>
      <email>veerle.visser-vandewalle@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jens KUHN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veerle VISSER-VANDEWALLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center The Hebrew University</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zvi ISRAEL, MD</last_name>
      <email>israelz@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Renana EITAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hagaï BERGMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zvi ISRAEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DISS - Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orsola GAMBINI, MD</last_name>
      <phone>+39 0250323132</phone>
      <email>orsola.gambini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Angelo FRANZINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orsola GAMBINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaston SCHECHTMANN, MD PhD</last_name>
      <phone>+46 70 403 5999</phone>
      <email>gaston.schechtmann@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Diana DJURFELDT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaston SCHECHTMANN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul KRACK, MD PhD</last_name>
      <email>paul.krack@ujf-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Shahan MOMJIAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joao FLORES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul KRACK, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Subramaniam M, Soh P, Vaingankar JA, Picco L, Chong SA. Quality of life in obsessive-compulsive disorder: impact of the disorder and of treatment. CNS Drugs. 2013 May;27(5):367-83. doi: 10.1007/s40263-013-0056-z. Review.</citation>
    <PMID>23580175</PMID>
  </reference>
  <reference>
    <citation>Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.</citation>
    <PMID>19005196</PMID>
  </reference>
  <reference>
    <citation>Kohl S, Schönherr DM, Luigjes J, Denys D, Mueller UJ, Lenartz D, Visser-Vandewalle V, Kuhn J. Deep brain stimulation for treatment-refractory obsessive compulsive disorder: a systematic review. BMC Psychiatry. 2014 Aug 2;14:214. doi: 10.1186/s12888-014-0214-y.</citation>
    <PMID>25085317</PMID>
  </reference>
  <reference>
    <citation>Eitan R, Shamir RR, Linetsky E, Rosenbluh O, Moshel S, Ben-Hur T, Bergman H, Israel Z. Asymmetric right/left encoding of emotions in the human subthalamic nucleus. Front Syst Neurosci. 2013 Oct 29;7:69. doi: 10.3389/fnsys.2013.00069. eCollection 2013.</citation>
    <PMID>24194703</PMID>
  </reference>
  <reference>
    <citation>Mataix-Cols D, Fernández de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016 Feb;15(1):80-1. doi: 10.1002/wps.20299.</citation>
    <PMID>26833615</PMID>
  </reference>
  <reference>
    <citation>Piallat B, Polosan M, Fraix V, Goetz L, David O, Fenoy A, Torres N, Quesada JL, Seigneuret E, Pollak P, Krack P, Bougerol T, Benabid AL, Chabardès S. Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease. Ann Neurol. 2011 May;69(5):793-802. doi: 10.1002/ana.22222. Epub 2010 Dec 28.</citation>
    <PMID>21520240</PMID>
  </reference>
  <reference>
    <citation>Ooms P, Mantione M, Figee M, Schuurman PR, van den Munckhof P, Denys D. Deep brain stimulation for obsessive-compulsive disorders: long-term analysis of quality of life. J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):153-8. doi: 10.1136/jnnp-2012-302550. Epub 2013 May 28.</citation>
    <PMID>23715912</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

